drugset / Trial / NCT05978284
Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a multi-center, open-label, Phase Ⅰ/Ⅱ clinical study of ZG006 for the treatment of participants with small cell lung cancer or neuroendocrine carcinoma who had no standard treatment available, or were intolerant to standard treatment.
Timeline
- Start
- 2023-10-27
- Primary completion
- 2026-09
- Completion
- 2026-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ZG006 | Unknown | 0.03 mg | Intravenous |
| Subject | ZG006 | Unknown | 0.1 mg | Intravenous |